Increase of c-FOS promoter transcriptional activity by the dual leucine zipper kinase.


Journal

Naunyn-Schmiedeberg's archives of pharmacology
ISSN: 1432-1912
Titre abrégé: Naunyn Schmiedebergs Arch Pharmacol
Pays: Germany
ID NLM: 0326264

Informations de publication

Date de publication:
06 2023
Historique:
received: 27 07 2022
accepted: 20 01 2023
medline: 17 5 2023
pubmed: 27 1 2023
entrez: 26 1 2023
Statut: ppublish

Résumé

The dual leucine zipper kinase (DLK) and the ubiquitously expressed transcription factor c-FOS have important roles in beta-cell proliferation and function. Some studies in neuronal cells suggest that DLK can influence c-FOS expression. Given that c-FOS is mainly regulated at the transcriptional level, the effect of DLK on c-FOS promoter activity was investigated in the beta-cell line HIT. The methods used in this study are the following: Luciferase reporter gene assays, immunoblot analysis, CRISPR-Cas9-mediated genome editing, and real-time quantitative PCR. In the beta-cell line HIT, overexpressed DLK increased c-FOS promoter activity twofold. Using 5'-,3'-promoter deletions, the promoter regions from - 348 to - 339 base pairs (bp) and from a - 284 to - 53 bp conferred basal activity, whereas the promoter region from - 711 to - 348 bp and from - 53 to + 48 bp mediated DLK responsiveness. Mutation of the cAMP response element within the promoter prevented the stimulatory effect of DLK. Treatment of HIT cells with KCl and the adenylate cyclase activator forskolin increased c-FOS promoter transcriptional activity ninefold. Since the transcriptional activity of those promoter fragments activated by KCl and forskolin was decreased by DLK, DLK might interfere with KCl/forskolin-induced signaling. In a newly generated, genome-edited HIT cell line lacking catalytically active DLK, c-Fos mRNA levels were reduced by 80% compared to the wild-type cell line. DLK increased c-FOS promoter activity but decreased stimulated transcriptional activity, suggesting that DLK fine-tunes c-FOS promoter-dependent gene transcription. Moreover, at least in HIT cells, DLK is required for FOS mRNA expression.

Identifiants

pubmed: 36700987
doi: 10.1007/s00210-023-02401-z
pii: 10.1007/s00210-023-02401-z
pmc: PMC10185614
doi:

Substances chimiques

Colforsin 1F7A44V6OU
MAP Kinase Kinase Kinases EC 2.7.11.25
Proto-Oncogene Proteins c-fos 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1223-1233

Subventions

Organisme : Deutsche Forschungsgemeinschaft
ID : OE 181/5-1

Informations de copyright

© 2023. The Author(s).

Références

Neurochem Int. 1998 Oct;33(4):287-97
pubmed: 9840219
Diabetologia. 1999 Feb;42(2):195-203
pubmed: 10064100
Nat Neurosci. 2014 Oct;17(10):1330-9
pubmed: 25195102
Exp Cell Res. 2019 Oct 15;383(2):111553
pubmed: 31415762
Histol Histopathol. 2009 Nov;24(11):1451-61
pubmed: 19760594
Mech Dev. 2018 Dec;154:73-81
pubmed: 29753813
Curr Opin Neurobiol. 2018 Dec;53:110-119
pubmed: 30053694
Cell Mol Life Sci. 2021 Jan;78(1):287-298
pubmed: 32189007
Mol Cell Biol. 1991 Mar;11(3):1270-80
pubmed: 1899906
FEBS Lett. 2016 Jun;590(12):1791-803
pubmed: 27164028
Annu Rev Cell Dev Biol. 2019 Oct 6;35:501-521
pubmed: 31590586
Cell. 2017 Jan 26;168(3):427-441.e21
pubmed: 28111074
Nat Biotechnol. 2015 May;33(5):538-42
pubmed: 25798939
J Neuroendocrinol. 2008 Jun;20(6):665-72
pubmed: 18601687
FASEB J. 2000 Jan;14(1):128-36
pubmed: 10627287
EMBO Rep. 2013 Jul;14(7):605-14
pubmed: 23681442
Genome Biol. 2016 Jul 05;17(1):148
pubmed: 27380939
Elife. 2017 Apr 25;6:
pubmed: 28440222
Neuron. 2008 Dec 10;60(5):775-87
pubmed: 19081374
Nat Biotechnol. 2015 May;33(5):543-8
pubmed: 25803306
Mol Cell. 2008 Mar 28;29(6):780-5
pubmed: 18374651
Nucleic Acids Res. 1991 Jul 11;19(13):3583-91
pubmed: 1906603
Diabetes. 1999 Oct;48(10):2007-14
pubmed: 10512366
Elife. 2016 Jun 07;5:
pubmed: 27268300
Naunyn Schmiedebergs Arch Pharmacol. 2017 Aug;390(8):813-825
pubmed: 28550372
Cell Signal. 2021 Jun;82:109953
pubmed: 33600948
Cell Signal. 2014 Sep;26(9):1792-9
pubmed: 24726898
Mol Pharmacol. 2008 Mar;73(3):652-9
pubmed: 18042735
Diabetologia. 2007 Aug;50(8):1678-87
pubmed: 17583797
Biochim Biophys Acta Rev Cancer. 2019 Aug;1872(1):11-23
pubmed: 31034924
Cell Signal. 2011 Feb;23(2):344-53
pubmed: 20940047
Mol Cell Biol. 2007 Apr;27(7):2431-41
pubmed: 17242197
Sci Rep. 2016 Aug 11;6:31482
pubmed: 27511108
Diabetologia. 2006 Feb;49(2):332-42
pubmed: 16369771
Cell Signal. 2013 Jan;25(1):113-25
pubmed: 23000340
Sci Transl Med. 2017 Aug 16;9(403):
pubmed: 28814543
Nat Cell Biol. 2002 May;4(5):E131-6
pubmed: 11988758
Proc Natl Acad Sci U S A. 2016 Jan 19;113(3):763-8
pubmed: 26719418
Diabetes. 2002 Apr;51(4):977-87
pubmed: 11916915
J Med Chem. 2015 Oct 22;58(20):8182-99
pubmed: 26431428
J Neurosci. 2006 Nov 15;26(46):11992-2002
pubmed: 17108173
Nat Protoc. 2013 Nov;8(11):2281-2308
pubmed: 24157548
Cell Signal. 2016 Apr;28(4):272-83
pubmed: 26776303
Expert Opin Ther Pat. 2016 May;26(5):607-16
pubmed: 27043251
Neurobiol Dis. 2019 Jul;127:178-192
pubmed: 30735704
FASEB J. 1998 Sep;12(12):1173-82
pubmed: 9737720
Endocrinology. 1996 Jan;137(1):225-33
pubmed: 8536617
J Exp Med. 2013 Nov 18;210(12):2553-67
pubmed: 24166713
J Cell Biol. 2013 Sep 2;202(5):747-63
pubmed: 23979718

Auteurs

Kyra-Alexandra Köster (KA)

Department of Clinical Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany.
DZHK Standort Hamburg, Kiel, Lübeck, Germany.

Jorge Duque Escobar (J)

Department of Clinical Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany.
DZHK Standort Hamburg, Kiel, Lübeck, Germany.

Anja Fietkau (A)

Department of Clinical Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany.

Regina Toledo (R)

Department of Clinical Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany.

Elke Oetjen (E)

Department of Clinical Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany. e.oetjen@uke.uni-hamburg.de.
DZHK Standort Hamburg, Kiel, Lübeck, Germany. e.oetjen@uke.uni-hamburg.de.
Institute of Pharmacy, University of Hamburg, Bundesstr. 45, 20146, Hamburg, Germany. e.oetjen@uke.uni-hamburg.de.

Articles similaires

Humans Endoribonucleases RNA, Messenger RNA Caps Gene Expression Regulation
Prader-Willi Syndrome Humans Angelman Syndrome CRISPR-Cas Systems Human Embryonic Stem Cells

A computational model for bacteriophage ϕX174 gene expression.

Alexis M Hill, Tanvi A Ingle, Claus O Wilke
1.00
Gene Expression Regulation, Viral Promoter Regions, Genetic Bacteriophage phi X 174 Computer Simulation Models, Genetic
Sirtuin 1 Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha Animals Resveratrol Rats

Classifications MeSH